Related Experiment Video
Updated: Jan 14, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Durable complete response with chemo-immuno-radiotherapy for metastatic cervical cancer progressing under
Thomas Westerhoff1, Nathalie Baudoux1, Manuela Undurraga2
1Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Objectives:
The prognosis for metastatic cervical cancer has dramatically improved in the past years with the addition of anti-PD1/PD-L1 immunotherapy to standard platinum-based chemotherapy +/-bevacizumab. Here, we aimed to investigate the benefit from combining chemo-immuno-radiotherapy for metastatic cervical cancer patients who had oligo-metastasis progression under maintenance immunotherapy, while the other metastatic sites are in remission.
Methods:
We report a case series of two patients diagnosed with multisite metastatic cervical cancer (including peritoneal carcinomatosis) who, after an initial response to pembrolizumab, presented with pelvic progression while maintaining complete regression of extra-pelvic metastases. Both patients underwent radical pelvic external beam radiotherapy (EBRT) and concomitant chemotherapy with weekly cisplatin +/- brachytherapy, while pursuing immunotherapy with pembrolizumab.
Results:
The two patients achieved durable complete response after completing this treatment scheme and tolerated it well. Patient 1 is in complete response 30 months after the end of chemo-radiotherapy. Patient 2 is in complete response 24 months after the end of chemo-radiotherapy.
Conclusions:
This case series suggests that chemo-immuno-radiotherapy with EBRT may represent a salvage treatment for patients who develop secondary loco-regional resistance to immunotherapy, as long as there is remission of the metastatic sites. Given the low response rate to chemotherapy in metastatic cervical cancer patients resistant to pembrolizumab, chemo-radiotherapy while pursuing immunotherapy should be investigated in highly selected patients with oligo-metastasis progression.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...